Nurix Therapeutics, Inc. (NRIX)
25.76
-0.02
(-0.08%)
USD |
NASDAQ |
Sep 01, 09:58
Nurix Therapeutics Cash from Operations (TTM) : -293.70M for May 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| May 31, 2026 | -293.70M |
| February 28, 2026 | -260.29M |
| November 30, 2025 | -249.46M |
| August 31, 2025 | -230.38M |
| May 31, 2025 | -215.18M |
| February 28, 2025 | -191.72M |
| November 30, 2024 | -172.58M |
| August 31, 2024 | -97.14M |
| May 31, 2024 | -96.10M |
| February 29, 2024 | -74.86M |
| November 30, 2023 | -81.36M |
| August 31, 2023 | -146.01M |
| May 31, 2023 | -151.18M |
| February 28, 2023 | -165.63M |
| Date | Value |
|---|---|
| November 30, 2022 | -159.81M |
| August 31, 2022 | -152.76M |
| May 31, 2022 | -136.43M |
| February 28, 2022 | -135.05M |
| November 30, 2021 | -84.36M |
| August 31, 2021 | -73.94M |
| May 31, 2021 | -50.10M |
| February 28, 2021 | -33.00M |
| November 30, 2020 | -0.08M |
| August 31, 2020 | 7.654M |
| May 31, 2020 | 50.17M |
| February 29, 2020 | 51.26M |
| November 30, 2019 | 0.601M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Monte Rosa Therapeutics, Inc. | -24.07M |
| Gilead Sciences, Inc. | 13.55B |
| TG Therapeutics, Inc. | 17.88M |
| Cue Biopharma, Inc. | -50.05M |
| Keros Therapeutics, Inc. | -47.99M |